LB Pharmaceuticals LBRX

Drug Manufacturers - General, Healthcare

$38.73

−1.75%

Market cap: $1.2B
PE: n/m; one or more of the four quarters through 2026-06-30 missing
Forward PE: n/m; not a meaningful number
Price to sales: n/m; not a meaningful number
EV/EBIT: n/m; a loss over the last year
Revenue, 12 months: n/m; not a meaningful number
Net margin: n/m; not a meaningful number
Free cash flow yield: −6.6%

Charts

Financials

Income statement for LBRX, by quarter
Income statement	Q3 FY24	Q4 FY24	Q1 FY25	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26
R&D	$10.7M	$376K	$3.4M	$2.4M	$2.4M−77%	$8.5M+2156%	$14.6M+328%	$44.1M+1724%
SG&A	$5.4M	$5.2M	$3M	$2.4M	$2.8M−48%	$5.4M+4%	$7.5M+148%	$9.8M+301%
Pre-tax income	−$14.2M	−$5.1M	−$5.3M	−$4.9M	−$3.6M−75%	−$11.5M+126%	−$19.1M+259%	−$51.6M+959%
	$0	$1K	$0	$0	$0	$1K+0%	$0	$0
Net income	−$14.2M	−$5.1M	−$5.3M	−$4.9M	−$3.6M−75%	−$11.5M+126%	−$19.1M+259%	−$51.6M+959%
	−$39.49	n/a	−$14.79	−$13.58	−$0.61−99%	n/a	−$0.67−96%	−$1.71−87%
	359.1K	n/a	358.8K	358.8K	5.8M+1517%	n/a	28.2M+7772%	30.1M+8299%

From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.

Peers

Companies in Drug Manufacturers - General nearest LB Pharmaceuticals' size, closest first.

Company	Market cap	PE	Its 10y median PE	P/S	Revenue growth	Net margin
LBRXLB Pharmaceuticals	$1.2B	n/m	n/a	n/m	n/m	n/m
OMEROmeros	$1.2B	10.9×	11.7×	n/m	n/m	n/m
PCRXPacira BioSciences	$1.5B	104×	65.6×	1.9×	+6%	2.0%
ANABAnaptysbio	$1.5B	10.7×	100.0×	n/m	n/m	n/m
AMPHAmphastar Pharmaceuticals	$1.1B	14.8×	20.6×	1.5×	+1%	10.8%
PAHCPhibro Animal Health	$1.6B	15.9×	21.5×	1.0×	+17%	6.6%
ANIPANI Pharmaceuticals	$1.7B	15.4×	60.6×	1.7×	+31%	11.1%
ABUSArbutus Biopharma	$831M	5.4×	5.6×	4.6×	n/m	84.2%
COLLCollegium Pharmaceutical	$747.5M	18.5×	19.1×	0.9×	+14%	5.9%
HRMYHarmony Biosciences	$2.1B	11.7×	13.8×	2.2×	+24%	18.9%
PBHPrestige Consumer Healthcare	$2.3B	13.4×	15.3×	2.0×	−1%	15.6%
Peer median	$1.5B	14.1×	19.9×	1.8×	+14%	10.9%